The hypothalamus and the pituitary gland constitute the "master tandem” of the human endocrine system, hence hypothalamic and/or pituitary disorders have broad and far-reaching implications for the function of the entire endocrine system. Implications of pituitary hyper- or hypofunction affect both issues directly linked with endocrine-related disorders (such as stature and reproductive function) as well as overall metabolic status related to glucose tolerance, bone metabolism and risk of cardiovascular disease. In such a setting, precise diagnosis and treatment of hypothalamic and pituitary disorders affect whole-body metabolic homeostasis. Furthermore, the pulsatile nature of pituitary hormone secretion implies that complex dynamic testing appears necessary in some cases of hypothalamic and pituitary diseases. Recent advances also cast a new light on the genetic background of several pituitary disorders, e.g. in cases of congenital hypopituitarism or Familial Isolated Pituitary adenomas (FIFA).
In the current issue, we aim to present the latest advances in the diagnosis of hypothalamic and pituitary disorders including optimisation of diagnostic procedures including (when applicable) appropriate genetic testing. This may also include differential diagnosis of posterior pituitary disorders i.e. diabetes insipidus versus psychogenic polydipsia. We also aim to address the health consequences of hypothalamic and pituitary diseases, including the impact of these conditions on cardiovascular, sexual and reproductive health as well as growth, bone metabolism and quality of life-related issues. We also aim to present papers that deal with the treatment of broad-spectrum hypothalamic and/or pituitary-related disorders, such as hypothalamic amenorrhoea, puberty-related disorders, secreting and non-secreting pituitary tumours, congenital hypopituitarism, hypophysitis, pituitary disorders during pregnancy, etc.
We invite both original and review papers that would address the following issues:
1. Advances in diagnosis of hypothalamic and/or pituitary disorders;
2. Metabolic and health consequences of hypothalamic and/or pituitary-related diseases;
3. Advances in treatment of hypothalamic and pituitary disorders.
The hypothalamus and the pituitary gland constitute the "master tandem” of the human endocrine system, hence hypothalamic and/or pituitary disorders have broad and far-reaching implications for the function of the entire endocrine system. Implications of pituitary hyper- or hypofunction affect both issues directly linked with endocrine-related disorders (such as stature and reproductive function) as well as overall metabolic status related to glucose tolerance, bone metabolism and risk of cardiovascular disease. In such a setting, precise diagnosis and treatment of hypothalamic and pituitary disorders affect whole-body metabolic homeostasis. Furthermore, the pulsatile nature of pituitary hormone secretion implies that complex dynamic testing appears necessary in some cases of hypothalamic and pituitary diseases. Recent advances also cast a new light on the genetic background of several pituitary disorders, e.g. in cases of congenital hypopituitarism or Familial Isolated Pituitary adenomas (FIFA).
In the current issue, we aim to present the latest advances in the diagnosis of hypothalamic and pituitary disorders including optimisation of diagnostic procedures including (when applicable) appropriate genetic testing. This may also include differential diagnosis of posterior pituitary disorders i.e. diabetes insipidus versus psychogenic polydipsia. We also aim to address the health consequences of hypothalamic and pituitary diseases, including the impact of these conditions on cardiovascular, sexual and reproductive health as well as growth, bone metabolism and quality of life-related issues. We also aim to present papers that deal with the treatment of broad-spectrum hypothalamic and/or pituitary-related disorders, such as hypothalamic amenorrhoea, puberty-related disorders, secreting and non-secreting pituitary tumours, congenital hypopituitarism, hypophysitis, pituitary disorders during pregnancy, etc.
We invite both original and review papers that would address the following issues:
1. Advances in diagnosis of hypothalamic and/or pituitary disorders;
2. Metabolic and health consequences of hypothalamic and/or pituitary-related diseases;
3. Advances in treatment of hypothalamic and pituitary disorders.